Special Issue "Antibiotics and Antimicrobials in Monkeypox and Other Emerging and Reemerging Zoonotic Diseases"
Deadline for manuscript submissions: 1 March 2024 | Viewed by 261
2. Latin American networks on Monkeypox Virus research (LAMOVI), Pereira, Risaralda, Colombia
3. Institución Universitaria Visión de las Américas, Pereira, Risaralda, Colombia
4. Master of Clinical Epidemiology and Biostatistics, Universidad Científica del Sur, Lima 4861, Peru
Interests: emerging infectious diseases; COVID-19; monkeypox virus
Special Issues, Collections and Topics in MDPI journals
Special Issue in Vaccines: Monkeypox Virus Infection: Analysis and Detection
Special Issue in Vaccines: Emerging and Reemerging Viral Infection, Immunopathogenesis and Diagnosis of Viral Infection, and Development of the Novel Antiviral Strategies
The Monkeypox (MPX) Public Health Emergency of International Concern (PHEIC), has reached so far, more than 100 countries in multiple continents, leading to more than 75,000 confirmed cases as of October 20, 2022. The implications of the management of patients including multiple aspects, such as the repurposing of antimicrobials, as in the case of antibiotics, but also the therapy of bacterial secondary infections and coinfections, particular associated with complications, such as pneumonia, sepsis, septic shock, skin infections, represent matters of concern, especially after the lessons derived from COVID-19 pandemic and the inappropriate use of antibiotics and antimicrobials. Additionally, in multiple other emerging and reemerging zoonoses, that may be bacterial, mycotic, viral and parasitic, such as plague, rabies, brucellosis, Lyme disease, leptospirosis, zoonotic influenza, among others; the proper use of antibiotics and antimicrobials is key for many of them. This Special Issue will present emerging concepts regarding the implications of antibiotics and antimicrobials use during the MPX multicountry outbreak, as well as on other emerging and reemerging zoonotic diseases, searching for further understanding of the current evidence and future scenarios.
Prof. Dr. Alfonso J. Rodriguez-Morales
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- clinical microbiology
- tropical and emergent pathogens
- molecular epidemiology
- antimicrobial stedwarship